The FDA's 2023 guidance on compounded peptides explicitly removed BPC-157 from the list of bulk drug substances eligible for compounding under Section 503A and 503B of the Federal Food, Drug, and Cosmetic Act
one dyspepsia, arthritis, and dizziness), and dosing with Nascobal (Cyanocobalamin, USP) Gel for Intranasal Administration (one headache, infection, and paresthesia)
Make sure to keep it out of sunlight, preferably in a cabinet
Physical therapy remains valuable alongside peptide use
Some common signs include persistent fatigue or weakness, trouble with balance, and that annoying pins and needles feeling in your hands or feet
As NAD+ levels decline with age, cellular function deteriorates, leading to visible and functional signs of aging